Cross-Sector entity
Paul Bolno is most often covered alongside GSK, which appears in 3 of these 3 stories. That works out to roughly 0.1 stories per week across a 160-day span. The busiest single day carried 2. Coverage clusters in market-trends, which accounts for 2 of those 3, with the remainder spread across 1 other category.
3 verified stories tracked
Last mentioned: Aug 4, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Paul Bolno is most often covered alongside GSK, which appears in 3 of these 3 stories. That works out to roughly 0.1 stories per week across a 160-day span. The busiest single day carried 2. Coverage clusters in market-trends, which accounts for 2 of those 3, with the remainder spread across 1 other category. Paul Bolno appears in 3 tracked Cross-Sector stories published from February 26, 2026 through August 4, 2026. Each carries 2 original sources on average.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Paul Bolno. Shared-story counts are live from our verified record — not editorial picks.
FY 2025 Earnings
Wave and Collegium release full-year financial results and 2026 guidance.
Anticipated Filing
Expected regulatory submission for WVE-N531 in Duchenne muscular dystrophy.
RNA Editing Milestone
WVE-006 demonstrates successful RNA editing in AATD patients.
DMD Breakthrough
Wave reports industry-leading dystrophin expression for WVE-N531.
Wave Life Sciences presented Phase I data for WVE-007, an siRNA targeting Activin E, demonstrating up to 88% serum reduction sustained for over 7.5 months. The INLIGHT Phase IIa trial is now enrolling 160 patients across four cohorts, with a focus on BMI 35–50 and type 2 diabetes status, aiming to validate the RNA editing platform's potential for durable obesity treatment.
Wave Life Sciences' WVE-007, a novel siRNA silencing Activin E, demonstrated a 16.5% improvement in visceral fat-to-muscle ratio in Phase I, outpacing existing therapies and offering a potential solution for the 70% of GLP-1 users who discontinue within a year. With enrollment underway in the INLIGHT Phase IIa trial, the 175 million individuals with obesity in the U.S. and Europe may soon have a longer-lasting, disease-modifying option.
Source: Motley Fool Transcribing (us) · fool.com
Wave Life Sciences and Collegium Pharmaceutical released their Q4 and full-year 2025 results, highlighting a pivotal year for RNA editing and specialty pain management. Wave's transition toward a commercial-stage biotech is accelerated by its GSK partnership and landmark clinical data in Alpha-1 antitrypsin deficiency.
Source: manilatimes.net · manilatimes.net
